
Opinion|Videos|January 7, 2025
Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care
Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and psychological support strategies employed to help patients navigate their lymphoma journey.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the key challenges that patients with diffuse large B-cell lymphoma (DLBCL) face at the time of diagnosis, and how do these challenges evolve throughout treatment?
- Can you discuss the same for patients with follicular lymphoma (FL)?
- How do you approach addressing the emotional and psychological challenges that patients with DLBCL and FL face, particularly when they first receive their diagnosis?
- What are the most important factors in helping patients navigate their journey with DLBCL or FL?
Advertisement
Related to this article

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.

Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.

FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
3
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
4
Up to 400 mg of Caffeine Daily Is Safe for Most Adults, AHA Says
5

